{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T13:02:42Z","timestamp":1789218162607,"version":"build-2803163510"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T00:00:00Z","timestamp":1766620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:title>Lay Summary<\/jats:title>\n                  <jats:p>There are limited data regarding pregnancy outcomes with maternal exposure to risankizumab, an anti\u2013interleukin 23 (IL-23) medication approved for Crohn disease and ulcerative colitis. In this multicenter study we analyzed maternal and pregnancy outcomes among women exposed to risankizumab prior to and during pregnancy. Among 444 women exposed to risankizumab, fewer than 10 patients had adverse pregnancy outcomes, including abortion or miscarriage, small for gestational age, stillbirth, gestational hypertension, preeclampsia, placenta previa, cesarean delivery, postpartum hemorrhage, or preterm prelabor rupture of membranes. There were zero cases of preterm birth across all subgroups. This is the largest known sample evaluating outcomes of risankizumab-exposed pregnancies, and the data are reassuring that risankizumab is safe to administer prior to and during pregnancy, though additional longitudinal studies are warranted to further assess the safety profile of risankizumab in pregnant patients.<\/jats:p>","DOI":"10.1093\/ibd\/izaf310","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T12:32:09Z","timestamp":1765197129000},"page":"820-823","source":"Crossref","is-referenced-by-count":1,"title":["Pregnancy and Maternal Outcomes After Exposure to Risankizumab During Pregnancy: A Multi-Center Experience in the United States"],"prefix":"10.1093","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6688-0552","authenticated-orcid":false,"given":"Rachel W","family":"Winter","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women\u2019s Hospital , Boston, MA,","place":["United States"]},{"name":"Harvard Medical School , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Yin","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Statistics, University of California, Davis , Davis, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2720-4404","authenticated-orcid":false,"given":"Sonia","family":"Friedman","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Tufts Medical Center , Boston, MA,","place":["United States"]},{"name":"Tufts University School of Medicine , Boston, MA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9394-4144","authenticated-orcid":false,"given":"Kevin Sheng-Kai","family":"Ma","sequence":"additional","affiliation":[{"name":"Center for Global Health, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,25]]},"reference":[{"key":"2026040214064455000_izaf310-B1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cgh.2020.09.021","article-title":"Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis","volume":"20","author":"Nielsen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026040214064455000_izaf310-B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjac115","article-title":"European Crohn\u2019s and colitis guidelines on sexuality, fertility, pregnancy, and lactation","volume":"17","author":"Torres","year":"2023","journal-title":"J Crohns Colitis"},{"key":"2026040214064455000_izaf310-B3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1093\/ibd\/izz037","article-title":"Inflammatory bowel disease in pregnancy clinical care pathway: a report from the American gastroenterological association IBD parenthood project working group","volume":"25","author":"Mahadevan","year":"2019","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214064455000_izaf310-B4","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1093\/ibd\/izaf171","article-title":"Global consensus statement on the management of pregnancy in inflammatory bowel disease","volume":"31","author":"Mahadevan","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214064455000_izaf310-B5","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1159\/000542217","article-title":"Biologics use for psoriasis during pregnancy and its related adverse outcomes in pregnant women and newborns: findings from WHO pharmacovigilance study","volume":"186","author":"Jeong","year":"2025","journal-title":"Int Arch Allergy Immunol"},{"key":"2026040214064455000_izaf310-B6","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/ibd\/izae182","article-title":"Low placental transfer rates of risankizumab among pregnant women with inflammatory bowel disease","volume":"30","author":"Mahadevan","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026040214064455000_izaf310-B7","doi-asserted-by":"publisher","first-page":"468","DOI":"10.14309\/ajg.0000000000002553","article-title":"Maternal and neonatal outcomes in vedolizumab- and ustekinumab-exposed pregnancies: results from the PIANO registry","volume":"119","author":"Chugh","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026040214064455000_izaf310-B8","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1093\/ecco-jcc\/jjac086","article-title":"Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal, and infant outcome: a prospective multicentre study","volume":"16","author":"Mitrova","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026040214064455000_izaf310-B9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.cgh.2023.12.029","article-title":"Safety of vedolizumab and ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease","volume":"23","author":"Meyer","year":"2025","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/4\/820\/66126697\/izaf310.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/32\/4\/820\/66126697\/izaf310.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T18:06:48Z","timestamp":1775153208000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/32\/4\/820\/8404598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,25]]},"references-count":9,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12,25]]},"published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf310","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,12,25]]}}}